Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience

Gynecologic Oncology Reports · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles